Epoetin Beta
When ATH:
B03XA01
Pharmacological action
Recombinant human erythropoietin (purified glycoprotein), It is a hematopoietic growth factor. Obtained by genetic engineering. Increases erythrocyte count, retikulotsitov, stimulates hemoglobin synthesis in cells. It does not affect leucopoiesis. It is believed, erythropoietin erythropoietin interacts with specific receptors on the cell surface.
Pharmacokinetics
After p / to the introduction of Cmax plasma achieved through 12-28 no. T1/2 in the final phase – 13-28 no.
After the on / in the T1/2 the active substance is 4-12 no.
Testimony
Severe anemia, It occurs in chronic renal failure.
Anemia in patients with lesions of bone marrow and some chronic diseases (incl. aplasticheskaya anemia, anemia in myelodysplastic diseases, chronic inflammatory diseases, AIDS, Cancer).
Preventing anemia in premature infants, born weighing 750-1500 g to 34 weeks of gestation.
To increase the volume of blood, intended for subsequent autotransfusion to avoid blood transfusions.
Dosage regimen
Doses, scheme and the duration of treatment set individually, depending on the severity of anemia, the severity of the patient's condition, nature of the disease. Enter p / and / in. The initial dose – 50-150 IU / kg, the frequency of administration – average 3 times a week.
Side effect
Cardio-vascular system: possible hypertension, hypertensive crisis.
CNS: possible encephalopathy (often with hypertensive crises), headache, confusion.
From the blood coagulation system: rarely – thrombocytosis, thrombotic complications.
Metabolism: rarely – hyperkalemia.
Allergic reactions: rarely – skin rash, anaphylactoid reactions.
Contraindications
Uncontrolled hypertension, myocardial infarction or cerebral stroke in the previous month, unstable angina, thromboembolism, Hypersensitivity to epoetin beta.
Pregnancy and lactation
During pregnancy and lactation epoetin beta is used only in the event, when the anticipated benefits of treatment to the mother outweighs the potential risk of side effects like his mother, and in the fetus or child.
IN experimental studies teratogenic effects were found.
Cautions
To use caution in epilepsy, thrombocytosis, hepatic insufficiency, vascular insufficiency, malignancy; patients with nephrosclerosis, not receiving hemodialysis, as it is possible more rapid deterioration of renal function.
The effectiveness of treatment is reduced in iron deficiency in the body, in infectious and inflammatory diseases, gemolize.
Effects on ability to drive vehicles and management mechanisms
During treatment should refrain from activities, require increased attention and psychomotor speed reactions.
Drug Interactions
With simultaneous use of drugs, affecting hematopoiesis (eg, iron supplementation), can amplify the stimulatory effect of epoetin beta.
